Chromosomal Crossover News and Research

RSS

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

Boehringer Ingelheim presented today for the first time data from a Phase II dose ranging study investigationg the combination of olodaterol, an investigational long-acting beta2-agonist (LABA), and tiotropium, a long-acting muscarinic antagonist (LAMA), in COPD patients, compared to the investigational agent olodaterol alone.

3 Sep 2012

Positive results from Elevation Pharmaceuticals’ EP-101 Phase 2b study on COPD

Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study – a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) – at the annual meeting of the European Respiratory Society in Vienna, Austria.

3 Sep 2012

Renal denervation safe and effective in patients with treatment resistant hypertension

Renal denervation leads to significant and sustained blood pressure reduction for up to 18 months in patients with treatment resistant hypertension, according to research presented at ESC Congress 2012.

27 Aug 2012

Study identifies how genetic mutations in the nervous system cause Duane Syndrome

A research team from King's College London and the University of Exeter Medical School has identified how a genetic mutation acts during the development of nerves responsible for controlling eye muscles, resulting in movement disorders such as Duane Syndrome, a form of squint.

22 Aug 2012

Resistant starch can help improve insulin sensitivity

Ingredion Incorporated, a leading global provider of ingredient solutions, today announced the results of a new independent clinical trial published in the September 2012 issue of the Journal of Clinical Endocrinology & Metabolism.

10 Aug 2012

Grapes reduce key risk factors for heart disease in men with metabolic syndrome

Consuming grapes may help protect heart health in people with metabolic syndrome, according to new research published in the Journal of Nutrition. Researchers observed a reduction in key risk factors for heart disease in men with metabolic syndrome: reduced blood pressure, improved blood flow and reduced inflammation. Natural components found in grapes, known as polyphenols, are thought to be responsible for these beneficial effects.

10 Aug 2012

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Breast cancer is the most important cancer for women in the developed world. About 20% of all patients diagnosed with breast cancer die of metastatic disease.

1 Aug 2012

Latest polypill trial yields largest improvements yet

The results of the first trial to administer the polypill on the basis of age alone has shown the largest reductions in blood pressure and cholesterol level of any polypill trial to date, researchers report.

24 Jul 2012

XenoPort initiates XP23829 Phase 1 study in healthy adults

XenoPort, Inc. announced today that the first subjects have been dosed in a Phase 1, randomized, double-blind, two-period crossover, food effect comparison study of XP23829 in healthy adults. The trial is designed to assess the pharmacokinetics, safety and tolerability of a single dose of XP23829 administered in both fasted and fed conditions.

24 Jul 2012

CPAP effectively reduces symptoms and improves QOL in sleepy patients with milder OSA

Continuous positive airway pressure (CPAP), well established as an effective treatment for severe obstructive sleep apnea (OSA), is also effective in patients with mild and moderately severe OSA and daytime sleepiness, according to a new study.

20 Jul 2012

Multi-well microplates ensure high filtered sample integrity

The need for reliable methods to purify samples and improve assays has led Porvair Sciences to develop a range of proprietary multi-well filtration microplates optimised for applications including cell harvesting, DNA separations, binding studies, plasmid isolation, general filtration and sample clean-up.

From Porvair Sciences Limited 10 Jul 2012

Telephone monitoring improves drug use, psychiatric symptoms

Patients being treated for a substance use disorder achieve significant short-term improvements in their drug use and psychiatric symptoms when receiving telephone continuing care, show study findings.

10 Jul 2012

New York Times examines bird flu studies, history of controversy

The New York Times examines several studies published in the journals Nature and Science looking at how the H5N1 bird flu virus could mutate to become more virulent among humans and outlines the history of controversy surrounding the studies.

27 Jun 2012

New drug better than chemotherapy for skin cancer patients

A new drug, dabrafenib, shows improvements over chemotherapy for patients suffering from a form of advanced skin cancer, according to the results of a Phase III study (“BREAK-3” trial) published Online First in the Lancet.

26 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

Major advance in development of night-time automatic control device for blood glucose levels at home

Yet another exciting breakthrough took place yesterday in the advancement and development of the ARTIFICIAL PANCREAS by specialists at Schneider Children's Medical Center of Israel.

18 Jun 2012

Civitas commences CVT-301 Phase 2a trial in Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today the initiation of a Phase 2a clinical trial in Parkinson's disease patients evaluating CVT-301, an inhaled formulation of levodopa (L-dopa), for the rapid relief from motor fluctuations.

16 Jun 2012

Long-term rhythm, not rate, control may prolong life with AF

Rhythm control therapy for atrial fibrillation may improve survival rates compared with rate control therapy when used long term, show study results published in the Archives of Internal Medicine.

15 Jun 2012

Dental profession needs to build a stronger connection between oral and general health

The dental profession needs to build a stronger connection between oral health and general health—not only for individual patients, but also at the community level, according to the special June issue of The Journal of Evidence-Based Dental Practice (JEBDP), the foremost publication of information about evidence-based dental practice, published by Elsevier.

5 Jun 2012

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

Active Biotech and Ipsen today presented overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific conference "2012 ASCO Annual Meeting" held in Chicago (USA).